| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Depressive Disorder | 34 | 2020 | 222 | 4.140 |
Why?
|
| Serotonin Uptake Inhibitors | 25 | 2020 | 71 | 2.700 |
Why?
|
| Depressive Disorder, Major | 23 | 2018 | 124 | 2.610 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 4 | 2024 | 39 | 2.410 |
Why?
|
| Depression | 17 | 2020 | 506 | 2.380 |
Why?
|
| Adolescent | 83 | 2025 | 3690 | 1.570 |
Why?
|
| Antidepressive Agents | 13 | 2019 | 156 | 1.170 |
Why?
|
| Male | 79 | 2025 | 10145 | 1.100 |
Why?
|
| Cyclohexanols | 17 | 2013 | 36 | 1.070 |
Why?
|
| Humans | 101 | 2025 | 17822 | 1.070 |
Why?
|
| Female | 76 | 2025 | 12780 | 0.980 |
Why?
|
| Child of Impaired Parents | 7 | 2020 | 33 | 0.910 |
Why?
|
| Prediabetic State | 1 | 2024 | 56 | 0.890 |
Why?
|
| Suicide | 8 | 2022 | 124 | 0.880 |
Why?
|
| Treatment Outcome | 34 | 2022 | 1265 | 0.840 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 8 | 2018 | 14 | 0.830 |
Why?
|
| Internet | 5 | 2013 | 231 | 0.830 |
Why?
|
| Blood Glucose | 1 | 2024 | 349 | 0.810 |
Why?
|
| Child | 26 | 2020 | 2497 | 0.750 |
Why?
|
| Suicide, Attempted | 7 | 2025 | 102 | 0.670 |
Why?
|
| Cost-Benefit Analysis | 5 | 2019 | 250 | 0.660 |
Why?
|
| Mental Disorders | 6 | 2013 | 280 | 0.640 |
Why?
|
| Mental Health Services | 4 | 2025 | 159 | 0.640 |
Why?
|
| Psychiatric Status Rating Scales | 18 | 2018 | 125 | 0.620 |
Why?
|
| Sleep Wake Disorders | 3 | 2013 | 37 | 0.580 |
Why?
|
| Antidepressive Agents, Second-Generation | 7 | 2013 | 28 | 0.570 |
Why?
|
| Primary Health Care | 6 | 2019 | 770 | 0.510 |
Why?
|
| Health Services Accessibility | 4 | 2013 | 292 | 0.510 |
Why?
|
| Adult | 27 | 2025 | 7708 | 0.490 |
Why?
|
| Self-Injurious Behavior | 4 | 2022 | 45 | 0.480 |
Why?
|
| Pain | 2 | 2012 | 79 | 0.480 |
Why?
|
| Parents | 7 | 2020 | 297 | 0.470 |
Why?
|
| Fluoxetine | 9 | 2013 | 26 | 0.460 |
Why?
|
| Combined Modality Therapy | 19 | 2013 | 147 | 0.460 |
Why?
|
| Psychiatry | 2 | 2013 | 23 | 0.450 |
Why?
|
| Psychotherapy, Group | 6 | 2013 | 26 | 0.440 |
Why?
|
| Patient Education as Topic | 5 | 2024 | 213 | 0.430 |
Why?
|
| Telemedicine | 2 | 2013 | 187 | 0.420 |
Why?
|
| Quality of Life | 6 | 2020 | 511 | 0.400 |
Why?
|
| Refugees | 7 | 1997 | 11 | 0.400 |
Why?
|
| Venlafaxine Hydrochloride | 17 | 2013 | 37 | 0.390 |
Why?
|
| Follow-Up Studies | 13 | 2018 | 1219 | 0.390 |
Why?
|
| Young Adult | 9 | 2025 | 2464 | 0.380 |
Why?
|
| Stress Disorders, Post-Traumatic | 7 | 1997 | 58 | 0.360 |
Why?
|
| Psychotherapy | 5 | 2013 | 59 | 0.350 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2019 | 391 | 0.350 |
Why?
|
| Self-Help Groups | 2 | 2013 | 30 | 0.340 |
Why?
|
| Acute Coronary Syndrome | 2 | 2020 | 18 | 0.330 |
Why?
|
| Cognition | 3 | 2018 | 83 | 0.320 |
Why?
|
| Suicidal Ideation | 6 | 2022 | 101 | 0.320 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 332 | 0.320 |
Why?
|
| Health Maintenance Organizations | 5 | 2005 | 417 | 0.310 |
Why?
|
| Drug Resistance | 11 | 2012 | 32 | 0.310 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2018 | 2 | 0.300 |
Why?
|
| Patient Compliance | 4 | 2019 | 301 | 0.290 |
Why?
|
| Self Care | 2 | 2005 | 163 | 0.270 |
Why?
|
| United States | 16 | 2025 | 4007 | 0.270 |
Why?
|
| Middle Aged | 10 | 2025 | 8020 | 0.260 |
Why?
|
| Community Mental Health Services | 4 | 2001 | 33 | 0.260 |
Why?
|
| Cost of Illness | 1 | 2006 | 93 | 0.260 |
Why?
|
| Research Design | 5 | 2020 | 376 | 0.260 |
Why?
|
| Mass Screening | 3 | 2020 | 678 | 0.250 |
Why?
|
| Paroxetine | 7 | 2013 | 23 | 0.240 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2019 | 329 | 0.240 |
Why?
|
| Blood Glucose Self-Monitoring | 1 | 2024 | 46 | 0.230 |
Why?
|
| Sleep | 1 | 2024 | 58 | 0.230 |
Why?
|
| Outpatients | 1 | 2025 | 110 | 0.230 |
Why?
|
| Insulin Resistance | 1 | 2024 | 137 | 0.220 |
Why?
|
| Actigraphy | 2 | 2015 | 16 | 0.220 |
Why?
|
| United States Food and Drug Administration | 2 | 2014 | 34 | 0.210 |
Why?
|
| Ambulatory Care | 1 | 2025 | 247 | 0.210 |
Why?
|
| Adolescent Behavior | 4 | 2013 | 127 | 0.210 |
Why?
|
| Fatigue | 2 | 2013 | 34 | 0.200 |
Why?
|
| Adaptation, Psychological | 3 | 2009 | 77 | 0.200 |
Why?
|
| International Classification of Diseases | 1 | 2022 | 85 | 0.200 |
Why?
|
| Patient Care | 1 | 2022 | 35 | 0.190 |
Why?
|
| Aged | 5 | 2024 | 6173 | 0.190 |
Why?
|
| Time Factors | 7 | 2012 | 1097 | 0.190 |
Why?
|
| Psychotropic Drugs | 3 | 2009 | 36 | 0.190 |
Why?
|
| Child Behavior Disorders | 2 | 2005 | 17 | 0.190 |
Why?
|
| Health Services | 1 | 2022 | 113 | 0.180 |
Why?
|
| Emergency Services, Psychiatric | 1 | 2000 | 1 | 0.180 |
Why?
|
| Comorbidity | 11 | 2013 | 597 | 0.180 |
Why?
|
| Citalopram | 5 | 2013 | 14 | 0.180 |
Why?
|
| Mother-Child Relations | 1 | 2020 | 14 | 0.180 |
Why?
|
| Maternal Behavior | 1 | 2020 | 13 | 0.180 |
Why?
|
| Homeless Persons | 1 | 2000 | 26 | 0.170 |
Why?
|
| Psychology, Adolescent | 3 | 2016 | 14 | 0.170 |
Why?
|
| Sleep Hygiene | 1 | 2020 | 3 | 0.170 |
Why?
|
| Trauma Severity Indices | 1 | 2020 | 8 | 0.170 |
Why?
|
| Parenting | 1 | 2020 | 29 | 0.170 |
Why?
|
| Severity of Illness Index | 5 | 2013 | 455 | 0.170 |
Why?
|
| Program Evaluation | 1 | 2000 | 223 | 0.160 |
Why?
|
| Patient Preference | 1 | 2020 | 48 | 0.160 |
Why?
|
| Dysthymic Disorder | 1 | 1999 | 6 | 0.160 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 91 | 0.160 |
Why?
|
| Health Promotion | 2 | 2018 | 281 | 0.160 |
Why?
|
| Patient Care Team | 3 | 2014 | 114 | 0.150 |
Why?
|
| Substance-Related Disorders | 5 | 2009 | 434 | 0.150 |
Why?
|
| Risk Factors | 9 | 2016 | 3362 | 0.150 |
Why?
|
| Oregon | 8 | 2006 | 181 | 0.150 |
Why?
|
| Health Policy | 2 | 2018 | 123 | 0.150 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 20 | 0.150 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2018 | 38 | 0.150 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 1323 | 0.150 |
Why?
|
| Population Surveillance | 2 | 2018 | 264 | 0.140 |
Why?
|
| Drug Substitution | 3 | 2012 | 10 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2024 | 755 | 0.140 |
Why?
|
| Anxiety | 2 | 2013 | 151 | 0.140 |
Why?
|
| Warfare | 1 | 1997 | 1 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 1 | 1997 | 15 | 0.140 |
Why?
|
| Double-Blind Method | 5 | 2018 | 160 | 0.130 |
Why?
|
| Treatment Refusal | 1 | 2016 | 33 | 0.130 |
Why?
|
| Patient Selection | 3 | 2012 | 190 | 0.120 |
Why?
|
| Social Environment | 1 | 1995 | 88 | 0.120 |
Why?
|
| Attitude to Health | 2 | 2012 | 165 | 0.120 |
Why?
|
| Recurrence | 4 | 2005 | 189 | 0.120 |
Why?
|
| Adolescent Psychiatry | 2 | 2004 | 2 | 0.120 |
Why?
|
| Child Psychiatry | 2 | 2004 | 3 | 0.120 |
Why?
|
| Mass Media | 1 | 2014 | 17 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2015 | 219 | 0.110 |
Why?
|
| Societies, Medical | 2 | 2004 | 75 | 0.110 |
Why?
|
| Child Abuse, Sexual | 2 | 2011 | 14 | 0.110 |
Why?
|
| Disease Management | 3 | 2013 | 135 | 0.110 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2014 | 95 | 0.110 |
Why?
|
| Age Factors | 5 | 2019 | 923 | 0.110 |
Why?
|
| Intelligence Tests | 1 | 1993 | 4 | 0.110 |
Why?
|
| Disaster Medicine | 1 | 2013 | 2 | 0.110 |
Why?
|
| Computers, Handheld | 1 | 2013 | 11 | 0.110 |
Why?
|
| Conflict (Psychology) | 1 | 2013 | 7 | 0.110 |
Why?
|
| Language | 1 | 1993 | 53 | 0.110 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 151 | 0.110 |
Why?
|
| Prospective Studies | 6 | 2018 | 1286 | 0.100 |
Why?
|
| Rural Population | 1 | 2013 | 52 | 0.100 |
Why?
|
| Medical Informatics | 1 | 2013 | 38 | 0.100 |
Why?
|
| Mobile Applications | 1 | 2013 | 19 | 0.100 |
Why?
|
| Health Behavior | 3 | 2018 | 360 | 0.100 |
Why?
|
| Text Messaging | 1 | 2013 | 29 | 0.100 |
Why?
|
| Alkaptonuria | 1 | 2012 | 1 | 0.100 |
Why?
|
| Hydrolases | 1 | 2012 | 1 | 0.100 |
Why?
|
| Hepatocytes | 1 | 2012 | 2 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 3 | 0.100 |
Why?
|
| Parent-Child Relations | 1 | 2013 | 55 | 0.100 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 93 | 0.100 |
Why?
|
| Cambodia | 7 | 1997 | 11 | 0.100 |
Why?
|
| Football | 4 | 2001 | 5 | 0.100 |
Why?
|
| Anhedonia | 1 | 2012 | 5 | 0.100 |
Why?
|
| Trazodone | 1 | 2012 | 1 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 186 | 0.100 |
Why?
|
| Personality Assessment | 4 | 2012 | 15 | 0.100 |
Why?
|
| Quality Indicators, Health Care | 1 | 2013 | 182 | 0.100 |
Why?
|
| Chronic Pain | 1 | 2013 | 127 | 0.090 |
Why?
|
| Self Mutilation | 1 | 2011 | 1 | 0.090 |
Why?
|
| Referral and Consultation | 2 | 2019 | 169 | 0.090 |
Why?
|
| Linear Models | 1 | 2012 | 232 | 0.090 |
Why?
|
| Body Mass Index | 2 | 2013 | 967 | 0.090 |
Why?
|
| Retrospective Studies | 4 | 2020 | 2467 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2011 | 21 | 0.090 |
Why?
|
| Algorithms | 2 | 2019 | 239 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2012 | 1424 | 0.090 |
Why?
|
| Longitudinal Studies | 4 | 2017 | 720 | 0.090 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2009 | 2 | 0.090 |
Why?
|
| Health Education | 4 | 2001 | 111 | 0.090 |
Why?
|
| Drug Therapy, Combination | 4 | 2011 | 115 | 0.080 |
Why?
|
| Problem Solving | 1 | 2009 | 10 | 0.080 |
Why?
|
| Behavior Therapy | 2 | 1996 | 146 | 0.080 |
Why?
|
| Street Drugs | 1 | 2009 | 13 | 0.080 |
Why?
|
| Social Behavior | 1 | 2009 | 23 | 0.080 |
Why?
|
| Family | 4 | 2016 | 112 | 0.080 |
Why?
|
| Mood Disorders | 2 | 2001 | 19 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 86 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1120 | 0.080 |
Why?
|
| Anabolic Agents | 3 | 2001 | 3 | 0.080 |
Why?
|
| Conduct Disorder | 2 | 2009 | 7 | 0.080 |
Why?
|
| Prefrontal Cortex | 2 | 2018 | 6 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 379 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2011 | 246 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2009 | 30 | 0.070 |
Why?
|
| Washington | 3 | 2006 | 383 | 0.070 |
Why?
|
| Feeding Behavior | 1 | 2008 | 166 | 0.070 |
Why?
|
| Bipolar Disorder | 2 | 2012 | 59 | 0.070 |
Why?
|
| Program Development | 3 | 2002 | 69 | 0.070 |
Why?
|
| Single-Blind Method | 2 | 2019 | 45 | 0.070 |
Why?
|
| Proportional Hazards Models | 4 | 2011 | 711 | 0.070 |
Why?
|
| Antisocial Personality Disorder | 1 | 2006 | 3 | 0.070 |
Why?
|
| Alcoholism | 1 | 2009 | 348 | 0.060 |
Why?
|
| Cues | 1 | 2005 | 10 | 0.060 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2025 | 25 | 0.060 |
Why?
|
| Psychometrics | 3 | 2012 | 121 | 0.060 |
Why?
|
| Placebos | 1 | 2004 | 21 | 0.060 |
Why?
|
| Telephone | 1 | 2005 | 161 | 0.060 |
Why?
|
| Interview, Psychological | 2 | 2016 | 19 | 0.060 |
Why?
|
| Logistic Models | 3 | 2009 | 928 | 0.060 |
Why?
|
| Exercise | 1 | 2008 | 495 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2004 | 132 | 0.060 |
Why?
|
| Schools | 3 | 2001 | 87 | 0.050 |
Why?
|
| Drug Labeling | 2 | 2014 | 14 | 0.050 |
Why?
|
| Quality Improvement | 1 | 2025 | 194 | 0.050 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2018 | 228 | 0.050 |
Why?
|
| Remission Induction | 2 | 2013 | 26 | 0.050 |
Why?
|
| Psychotherapy, Brief | 1 | 2001 | 20 | 0.050 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 2 | 2013 | 10 | 0.050 |
Why?
|
| Databases, Factual | 1 | 2002 | 315 | 0.050 |
Why?
|
| Affect | 2 | 2012 | 25 | 0.050 |
Why?
|
| Sex Factors | 2 | 2019 | 644 | 0.050 |
Why?
|
| Drug Interactions | 2 | 2012 | 20 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2010 | 35 | 0.040 |
Why?
|
| Sports | 1 | 2000 | 21 | 0.040 |
Why?
|
| Risk | 2 | 2015 | 518 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 2011 | 85 | 0.040 |
Why?
|
| Personality Inventory | 2 | 2009 | 14 | 0.040 |
Why?
|
| Professional Practice | 1 | 1999 | 16 | 0.040 |
Why?
|
| Task Performance and Analysis | 1 | 1999 | 12 | 0.040 |
Why?
|
| Mentoring | 1 | 2019 | 26 | 0.040 |
Why?
|
| Retreatment | 1 | 1999 | 10 | 0.040 |
Why?
|
| Family Therapy | 1 | 1999 | 6 | 0.040 |
Why?
|
| Case Management | 1 | 1999 | 33 | 0.040 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2013 | 3 | 0.040 |
Why?
|
| Memory | 1 | 2018 | 12 | 0.040 |
Why?
|
| Outcome and Process Assessment (Health Care) | 2 | 1997 | 102 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2018 | 41 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 131 | 0.040 |
Why?
|
| Mental Health | 1 | 2019 | 166 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 189 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 1997 | 22 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 354 | 0.040 |
Why?
|
| Motor Cortex | 1 | 2017 | 3 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2018 | 109 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 1996 | 141 | 0.040 |
Why?
|
| Health Status | 1 | 2019 | 299 | 0.040 |
Why?
|
| Psychotic Disorders | 1 | 1997 | 44 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 630 | 0.030 |
Why?
|
| Utah | 1 | 1997 | 33 | 0.030 |
Why?
|
| Doping in Sports | 1 | 1996 | 1 | 0.030 |
Why?
|
| Factor Analysis, Statistical | 1 | 1997 | 35 | 0.030 |
Why?
|
| Developing Countries | 1 | 1996 | 16 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2008 | 382 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 40 | 0.030 |
Why?
|
| Intergenerational Relations | 1 | 1995 | 3 | 0.030 |
Why?
|
| Social Adjustment | 2 | 2011 | 15 | 0.030 |
Why?
|
| Asian Americans | 1 | 1996 | 176 | 0.030 |
Why?
|
| Hospitalization | 1 | 2000 | 810 | 0.030 |
Why?
|
| Education | 2 | 2004 | 17 | 0.030 |
Why?
|
| Survival Analysis | 1 | 1995 | 216 | 0.030 |
Why?
|
| Age of Onset | 1 | 1994 | 79 | 0.030 |
Why?
|
| Language Tests | 1 | 1993 | 1 | 0.030 |
Why?
|
| Trail Making Test | 1 | 1993 | 2 | 0.030 |
Why?
|
| Time | 1 | 2013 | 20 | 0.030 |
Why?
|
| Virtual Reality Exposure Therapy | 1 | 2013 | 1 | 0.030 |
Why?
|
| United States Agency for Healthcare Research and Quality | 1 | 2013 | 14 | 0.030 |
Why?
|
| Behavioral Symptoms | 1 | 2013 | 4 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2018 | 1103 | 0.030 |
Why?
|
| Social Networking | 1 | 2013 | 20 | 0.030 |
Why?
|
| Social Media | 1 | 2013 | 12 | 0.030 |
Why?
|
| Butyrates | 1 | 2012 | 1 | 0.030 |
Why?
|
| Homogentisate 1,2-Dioxygenase | 1 | 2012 | 1 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2012 | 2 | 0.030 |
Why?
|
| Kinetics | 1 | 2012 | 12 | 0.030 |
Why?
|
| Organophosphorus Compounds | 1 | 2012 | 3 | 0.030 |
Why?
|
| Gene Expression | 1 | 2012 | 23 | 0.030 |
Why?
|
| Genetic Therapy | 1 | 2012 | 8 | 0.030 |
Why?
|
| Liver | 1 | 2012 | 33 | 0.030 |
Why?
|
| Mice | 1 | 2012 | 69 | 0.030 |
Why?
|
| Regression Analysis | 2 | 2004 | 300 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2012 | 2 | 0.020 |
Why?
|
| Syndrome | 1 | 2012 | 28 | 0.020 |
Why?
|
| Animals | 1 | 2012 | 262 | 0.020 |
Why?
|
| Ethnic Groups | 1 | 1995 | 485 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 321 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2001 | 159 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2014 | 2590 | 0.020 |
Why?
|
| Acculturation | 3 | 1996 | 20 | 0.020 |
Why?
|
| Prevalence | 3 | 2001 | 888 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2011 | 237 | 0.020 |
Why?
|
| Family Conflict | 1 | 2009 | 5 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2009 | 28 | 0.020 |
Why?
|
| Emotions | 1 | 2009 | 34 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2009 | 63 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 154 | 0.020 |
Why?
|
| Genotype | 1 | 2009 | 227 | 0.020 |
Why?
|
| Retention (Psychology) | 1 | 2008 | 7 | 0.020 |
Why?
|
| Child Abuse | 1 | 2009 | 44 | 0.020 |
Why?
|
| Bias | 1 | 2009 | 103 | 0.020 |
Why?
|
| Calcium | 1 | 2008 | 35 | 0.020 |
Why?
|
| Benzodiazepines | 1 | 2009 | 29 | 0.020 |
Why?
|
| Bone Density | 1 | 2008 | 97 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 381 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 673 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 609 | 0.020 |
Why?
|
| Socialization | 1 | 2006 | 3 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 428 | 0.020 |
Why?
|
| Focus Groups | 1 | 2006 | 147 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2009 | 1335 | 0.020 |
Why?
|
| Incidence | 2 | 2001 | 1269 | 0.010 |
Why?
|
| Professional-Patient Relations | 1 | 2005 | 47 | 0.010 |
Why?
|
| Juvenile Delinquency | 1 | 2004 | 12 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2005 | 229 | 0.010 |
Why?
|
| Psychology | 1 | 2002 | 16 | 0.010 |
Why?
|
| Research | 1 | 2002 | 65 | 0.010 |
Why?
|
| Imipramine | 1 | 2001 | 2 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 2001 | 15 | 0.010 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2001 | 9 | 0.010 |
Why?
|
| ROC Curve | 1 | 2001 | 77 | 0.010 |
Why?
|
| Child Nutrition Sciences | 1 | 2001 | 1 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2001 | 129 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2001 | 190 | 0.010 |
Why?
|
| Adolescent Health Services | 1 | 2001 | 43 | 0.010 |
Why?
|
| Self Efficacy | 1 | 2001 | 68 | 0.010 |
Why?
|
| Child Health Services | 1 | 2001 | 113 | 0.010 |
Why?
|
| Quality Assurance, Health Care | 1 | 2001 | 169 | 0.010 |
Why?
|
| Organizational Culture | 1 | 1999 | 18 | 0.010 |
Why?
|
| Consumer Behavior | 1 | 1999 | 29 | 0.010 |
Why?
|
| Length of Stay | 1 | 1997 | 182 | 0.010 |
Why?
|
| Curriculum | 1 | 1996 | 36 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 2000 | 373 | 0.010 |
Why?
|
| Peer Group | 1 | 1996 | 48 | 0.010 |
Why?
|
| Models, Psychological | 1 | 1996 | 23 | 0.010 |
Why?
|
| Thailand | 1 | 1996 | 3 | 0.010 |
Why?
|
| Life Change Events | 1 | 1996 | 31 | 0.010 |
Why?
|
| Urban Population | 1 | 1996 | 116 | 0.010 |
Why?
|
| Forecasting | 1 | 1996 | 75 | 0.010 |
Why?
|
| Social Class | 1 | 1995 | 121 | 0.010 |
Why?
|
| Fathers | 1 | 1994 | 10 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1994 | 60 | 0.010 |
Why?
|
| Mothers | 1 | 1994 | 106 | 0.010 |
Why?
|